NCT00027365 - An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 2003

Conditions

HIV Infections

Interventions

BIOLOGICAL

Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A

BIOLOGICAL

NefTat

DRUG

AS02A Adjuvant

BIOLOGICAL

gp120W61D

Trial Locations (15)

10021

NY Blood Ctr./Union Square CRS, New York

10456

NY Blood Ctr./Bronx CRS, The Bronx

14642

Univ. of Rochester HVTN CRS, Rochester

21205

Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research, Project SAVE-Baltimore, Baltimore

35294

Alabama Vaccine CRS, Birmingham

37232

Vanderbilt Vaccine CRS, Nashville

63110

Saint Louis Univ. School of Medicine, HVTU, St Louis

94102

San Francisco Vaccine and Prevention CRS, San Francisco

Unknown

Project Brave HIV Vaccine CRS, Baltimore

HIV Prevention & Treatment CRS, New York

Infectious Diseases Physicians, Inc., Annandale

FHCRC/UW Vaccine CRS, Seattle

02115

Brigham and Women's Hosp. CRS, Boston

Fenway Community Health Clinical Research Site (FCHCRS), Boston

02906

Miriam Hospital's HVTU, Providence

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH